Drug Database
TR

triamcinolone acetonide + moxifloxicin + vancomycin

✓ Approved

Harrow Health, Inc. · NR3C1 · Small Molecule

What is triamcinolone acetonide + moxifloxicin + vancomycin?

triamcinolone acetonide + moxifloxicin + vancomycin is a small molecule developed by Harrow Health, Inc.. It is approved for therapeutic indications via injectable (others) or intraocular injection.

Drug Profile

CompanyHarrow Health, Inc.
Drug ClassSmall Molecule
Molecular TargetNR3C1, ,
RouteInjectable (Others), Intraocular Injection
StatusApproved
Sources: ClinicalTrials.gov, Harrow Health, Inc.

Mechanism of Action

Molecular Targets

triamcinolone acetonide + moxifloxicin + vancomycin acts on 3 molecular targets:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
()
DNA gyrase subunit A, Staphylococcus aureus MRSA ()
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

triamcinolone acetonide + moxifloxicin + vancomycin is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Eye disordersCataract✓ Approved
Infections and infestationsEye infection✓ Approved
Eye disordersGlaucoma✓ Approved

Related Research Articles

PubMedScandinavian journal of clinical and laboratory investigation2026-10-16

Vancomycin therapeutic drug monitoring: trends and seasonal patterns.

Larsson Anders A, Hallberg Pär P, Cedernaes Jonathan J, Hamberg Anna-Karin AK

Vancomycin is widely used for serious Gram-positive infections, but its narrow therapeutic index necessitates therapeutic drug monitoring (TDM). Over recent decades, monitoring has shifted from trough-based to AUC-guided dosing. This study investigated long-term trends in vancomycin concentrations, seasonal variation and the utility of patient medians as a laboratory quality tool. Serum vancomycin results (n = 59,445) from routine TDM at Akademiska Hospital, Uppsala, Sweden (2006-2024) were analyzed. Data included sampling date, age, sex and concentration. Measurements were performed using validated immunoassays (Architect ci8200 and Cobas Pro c503) with standard quality control. Annual medians and percentiles were calculated, and seasonal variation was assessed. The number of analyses increased from 2,263 (2006) to 4,164 (2015), then declined to 2,414 (2024). Median concentrations and distribution percentiles rose steadily from 2006 to 2015 and remained stable thereafter. Seasonal variation showed a ∼15% decrease in testing volume during July-August, while concentration percentiles remained consistent throughout the year. Vancomycin concentrations in routine TDM increased until 2015 and have since stabilized, despite seasonal variation in test volume. Patient medians were stable over time and may serve as a useful complement to traditional quality control, particularly when standard materials do not fully represent patient samples.

PMID 42886031
Read full article →
PubMedTherapeutic drug monitoring2026-10-16

Effect of Vasopressin Infusion Rate on Vancomycin Dose Adjustment in Pediatric Central Diabetes Insipidus: Grand Round/A Case Study.

Ono Hiroyuki H, Tashiro Sho S, Tanaka Ryota R, Kohri Nao N et al.

Vancomycin (VCM)-associated acute kidney injury is a clinically important adverse event. Appropriate dose adjustment requires knowledge of factors influencing VCM clearance; however, these factors remain poorly characterized in pediatric patients. We report a pediatric case in which elevated blood VCM concentrations seemed to be associated with an increased arginine vasopressin (AVP) infusion rate. A 9-month-old female infant (6.9 kg, 64 cm) underwent craniotomy for hematoma removal after a traumatic fall. Postoperatively, a surgical site infection was suspected, and VCM was initiated at 90 mg every 6 hours. Initial therapeutic drug monitoring (TDM) showed a trough concentration (Ctrough) of 6.3 mcg/mL, below therapeutic range for pediatric patients. The VCM dose was increased to 140 mg every 6 hours. Repeat TDM showed a Ctrough of 19.0 mcg/mL. Before VCM initiation, the patient was administered continuous AVP infusion for central diabetes insipidus (CDI) associated with trauma. During VCM therapy, the AVP infusion rate was increased from 0.6 to 1.0 mL/h because of increased urine output, but urine output remained unchanged. After the elevated Ctrough, the VCM dose was reduced to 90 mg every 6 hours, whereas the AVP infusion rate was increased further to 3.2 mL/h. TDM performed before the fourth dose after dose reduction showed a Ctrough of 10.5 mcg/mL, approximately twice the initial concentration despite the same VCM dosage. Increased AVP infusion may have reduced the glomerular filtration rate and elevated the blood VCM concentration, independent of urine output. To our knowledge, this is the first pediatric case reporting elevated blood VCM concentrations associated with an increased AVP infusion rate despite persistent urine output in a patient with CDI. Clinicians should be aware that changes in AVP infusion rates may influence VCM exposure, and closer TDM may be warranted when AVP doses are adjusted.

PMID 42885999
Read full article →
PubMedDiagnostics (Basel, Switzerland)2026-10-16

Rapid CSF Molecular Diagnosis of Listeria monocytogenes Meningoencephalitis in an Elderly Immunocompetent Patient: A Case Report.

Andrejkovits Ákos Vince ÁV, Ladó Róbert R, Pop Adrian Vlad AV, Coșeriu Răzvan Lucian RL et al.

Background/Objectives: Listeria monocytogenes is an uncommon but potentially life-threatening cause of central nervous system infection, predominantly affecting older adults and immunocompromised patients. Neurolisteriosis may present with nonspecific neurological manifestations, and the absence of classical meningeal signs may delay diagnosis. We report a case of L. monocytogenes meningoencephalitis in an elderly patient without known immunosuppression, with rapid cerebrospinal fluid (CSF) molecular testing facilitating early diagnosis and appropriate antimicrobial treatment. Case presentation: A 76-year-old man with significant cardiovascular comorbidities was admitted with a 3-day history of fever, headache, nausea, vomiting, fatigue, and gait instability. He was alert on admission, with only mild meningeal signs, and initial cranial computed tomography showed no acute intracranial abnormalities. CSF analysis revealed inflammatory changes. Empirical ceftriaxone therapy was supplemented with vancomycin, followed by the initiation of intravenous ampicillin and gentamicin after molecular identification of L. monocytogenes. The diagnosis was subsequently confirmed by CSF culture, while blood cultures remained negative. Clinical and laboratory parameters improved progressively, accompanied by marked improvement in CSF findings on follow-up examination. The patient was discharged in stable condition after 18 days of hospitalization. Conclusions: Neurolisteriosis should be considered in elderly patients presenting with fever and neurological symptoms, even in the absence of overt immunosuppression or prominent meningeal signs. This case highlights the diagnostic value of rapid CSF molecular testing, particularly when blood cultures are negative and the initial clinical presentation is nonspecific. Early recognition of L. monocytogenes infection and timely initiation of targeted antimicrobial therapy are essential to improving outcomes.

PMID 42882317
Read full article →
PubMedThe Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians2026-10-15

The Impact of Empiric Linezolid Compared With Vancomycin on Inpatient Outcomes.

Excellent Stacey C SC, Hoffmann Jason J, Andrews Pamela P, Louzon Patricia R PR

Vancomycin and linezolid are commonly used for empiric treatment of methicillin-resistant Staphylococcus aureus (MRSA), but differences may influence the preferred agent. Vancomycin requires individualized dosing and drug monitoring, possibly delaying initiation. Linezolid offers fixed dosing, and potentially lower costs, which may improve time to first dose. This study compares clinical, operational, and cost outcomes associated with empiric vancomycin and linezolid use. This single-center, retrospective chart review included a convenience sample of 100 hospitalized adults receiving more than 1 dose of empiric vancomycin or linezolid, stratified by level of care (intensive care unit [ICU] vs non-ICU). The primary endpoint was 30-day all-cause mortality. Secondary endpoints included time to first dose, adverse events, therapy changes, treatment duration, length of stay (LOS), cost, and vancomycin dosing characteristics. A convenience sample of 100 patients (50 per group) was analyzed. Thirty-day all-cause mortality was 22% with vancomycin versus 12% with linezolid (P = .183). No statistically significant differences were observed in time to first dose (2.03 ± 1.51 hours vs 1.6 ± 1.66 hours, P = .180). No statistically significant difference was detected in therapy changes, treatment duration, hospital/ICU LOS, treatment failure, and adverse events. Vancomycin had a higher medication cost ($46.59 vs $29.52, P = .012). Patients receiving vancomycin had an average of 2.8 levels, requiring a median of 54.6 hours to reach therapeutic range, maintaining it for 29.5% of treatment duration. This study is limited by its retrospective design and small sample size. No statistically significant differences in clinical outcomes were detected between patients receiving empiric linezolid and vancomycin. Linezolid was associated with lower drug acquisition cost.

PMID 42876889
Read full article →
PubMedThe Annals of thoracic surgery2026-10-15

Topical Vancomycin for Prevention of Grade 2 or Higher Sternal Wound Infection After Cardiac Surgery: A Randomized Controlled Trial.

Tsai Meng-Ta MT, Li Chung-Yi CY, Chen Yi-Wen YW, Hu Yu-Ning YN et al.

To evaluate the efficacy and safety of topical vancomycin paste over the sternal edges in preventing sternal wound infection (SWI). This single-center, prospective, single-blind controlled trial 1:1 randomized 360 adult patients undergoing elective full sternotomy cardiac surgery to receive either vancomycin paste or normal saline (NCT04500275). The primary endpoint was SWI within 90 postoperative days. The secondary endpoints included postoperative acute kidney injury, emergence of resistant pathogens and systemic vancomycin exposure. The incidence of grade 2 or higher SWI within 90 days was significantly lower in the vancomycin group than in the placebo group (1 of 180, 0.6% vs. 7 of 180, 3.9%, p = .031). The subdistribution hazard ratio was 0.14 (p = .065). Deep SWI rate was 0.6% vs. 2.8% (p = .099). The incidence of acute kidney injury was comparable between the groups (31.7% vs. 28.9%, p = .251), even in patients with CKD stages ≥ 3. Systemic vancomycin concentrations were negligible and declined over time in non-dialysis patients. Levels above 10-20 mg/L persisted in some patients undergoing hemodialysis. Three cases of vancomycin-resistant Enterococcus from various sources were observed in the vancomycin group of patients with CKD stage ≥ 3 or undergoing hemodialysis. Topical vancomycin reduced grade 2 or higher SWI without increasing the risk of acute kidney injury. Systemic exposure was negligible, except in patients undergoing hemodialysis. While the emergence of VRE cannot be excluded, its incidence was negligible and does not outweigh the benefits of SWI reduction when using topical vancomycin.

PMID 42880620
Read full article →
PubMedGut microbes2026-10-15

Modulation of the gut microbiome and resistome by antibiotic use, but not by subsequent 2'-fucosyllactose intake, in adults with overweight or obesity.

Vliex Lars M M LMM, Godinho Mimoso Iúri F IF, Le Giang N GN, Blaak Ellen E EE et al.

Antibiotics are widely used to treat bacterial infections, yet overuse and misuse causes disruption of the gut microbiome and spread of antibiotic-resistant bacteria. Presence of antibiotic resistance genes (ARGs) could be a determinant of the response to antibiotics. Supplementation with prebiotics may limit the detrimental antibiotic-induced effects on the microbiome, but whether this results in changes in the gut resistome is unclear. This study investigated the impact of eight-week 2'-fucosyllactose (2'-FL) supplementation after seven-day vancomycin use in 18 adults with overweight/obesity, a subset from a double-blind placebo-controlled randomized intervention. Whole-metagenome shotgun sequencing was used to characterize the gut microbiome and resistome at baseline, after vancomycin use and after supplementation. Seven-day vancomycin use disrupted microbial richness and diversity (p < 0.001) and changed microbial composition. No improvements in microbial recovery were detected after eight week 2'-FL supplementation compared to placebo. Resistome richness and diversity were not affected by vancomycin use, although the presence of specific ARGs changed. No differential impact of 2'-FL supplementation on resistome richness, diversity and composition was detected. While vancomycin use disrupted the gut microbiome and affected the resistome, the detectable effects of 2'-FL supplementation were limited. Future research should investigate antibiotic- and prebiotic-induced changes in the gut resistome in more detail.

PMID 42878177
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about triamcinolone acetonide + moxifloxicin + vancomycin